A recent study indicates that individuals who discontinue blockbuster slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who end traditional diet and exercise regimens.
Research printed in a major health publication shows that while overweight people frequently drop about a fifth of their total mass while using the jabs, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying such medications need to be cognizant of the danger of quick weight regain when the treatment ends," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to starting weight within about a year and a half.
Weighing Approaches
The research, which reviewed dozens of trials involving over 9,000 of participants, contrasted the outcomes of these new drugs with conventional dieting.
The team point out that people who lose weight through dieting generally have a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Experts suggest the way of the jabs explains the amplified rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production may cause the system to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement leads to hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
The NHS recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts argue that, due to the likelihood of weight regain, the treatment should be considered ongoing.
This view is reinforced by drug manufacturers, who state that the findings "emphasize the long-term character of excess weight," comparing it to managing diseases like hypertension.
Patient Accounts
Users who have stopped the jabs explain a powerful return of appetite.
"It felt as if a switch flipping and you're instantly ravenous," said an individual.
This challenge is exacerbated if users have not developed permanent lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Use is greater among women than males.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on ongoing lifestyle support.